Eileen M. Handberg

Eileen M. Handberg

Auto-generated profile, based on publicly available information

Eileen M. Handberg

Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, FL (J.V., E.M.H., C.J.P.).

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2003 in JAMA
Verified
Journal Article
Open access
PDF file
CPCarl J. Pepine
Carl J. Pepine
EHEileen M. Handberg
Eileen M. Handberg
RCRhonda M. Cooper-DeHoff
Rhonda M. Cooper-DeHoff
RMRonald G. Marks
Ronald G. Marks
PKPeter Kowey
Peter Kowey
FIfor the INVEST Investigators
for the INVEST Investigators
Research from JAMA — A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease — The International Verapamil-Trandolapril Study (INVEST) — A Randomized Controlled Trial — ContextDespite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials.ObjectiveTo compare mortality and morbidity outcomes in patients with hypertension and CAD treated with a calcium antagonist strategy (CAS) or a non–calcium antagonist strategy (NCAS).Design, Setting, and ParticipantsRandomized, open label, blinded end point study of 22 576 hypertensive CAD patients aged 50 years or older, which was conducted September 1997 to February 2003 at 862 sites in 14 countries.InterventionsPatients were randomly assigned to either CAS (verapamil sustained release) or NCAS (atenolol). Strategies specified dose and additional drug regimens. Trandolapril and/or hydrochlorothiazide was administered to achieve blood pressure goals according to guidelines from the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) of less than 140 mm Hg (systolic) and less than 90 mm Hg (diastolic); and less than 130 mm Hg (systolic) and less than 85 mm Hg (diastolic) if diabetes or renal impairment was present. Trandolapril was also recommended for patients with heart failure, diabetes, or renal impairment.Main Outcome MeasuresPrimary: first occurrence of death (all cause), nonfatal myocardial infarction, or nonfatal stroke; other: cardiovascular death, angina, adverse experiences, hospitalizations, and blood pressure control at 24 months.ResultsAt 24 months, in the CAS group, 6391 patients (81.5%) were taking verapamil sustained release; 4934 (62.9%) were taking trandolapril; and 3430 (43.7%) were taking hydrochlorothiazide. In the NCAS group, 6083 patients (77.5%) were taking atenolol; 4733 (60.3%) were taking hydrochlorothiazide; and 4113 (52.4%) were taking trandolapril. After a follow-up of 61 835 patient-years (mean, 2.7 years per patient), 2269 patients had a primary outcome event with no statistically significant difference between treatment strategies (9.93% in CAS and 10.17% in NCAS; relative risk [RR], 0.98; 95% confidence interval [CI], 0.90-1.06). Two-year blood pressure control was similar between groups. The JNC VI blood pressure goals were achieved by 65.0% (systolic) and 88.5% (diastolic) of CAS and 64.0% (systolic) and 88.1% (diastolic) of NCAS patients. A total of 71.7% of CAS and 70.7% of NCAS patients achieved a systolic blood pressure of less than 140 mm Hg and diastolic blood pressure of less than 90 mm Hg.ConclusionThe verapamil-trandolapril–based strategy was as clinically effective as the atenolol-hydrochlorothiazide–based strategy in hypertensive CAD patients.

1 June 2010 in JACC
Verified
Journal Article
Closed access
CPCarl J Pepine
Carl J Pepine
RAR. David Anderson
R. David Anderson
BSBarry L. Sharaf
Barry L. Sharaf
SRSteven E. Reis
Steven E. Reis
KSKaren M. Smith
Karen M. Smith
C. Noel Bairey MerzC. Noel Bairey Merz
C. Noel Bairey Merz

1 July 1997 in American Heart Journal
Verified
Journal Article
Closed access
RCRobert M. Califf
Robert M. Califf
KAKirkwood F. Adams
Kirkwood F. Adams
WMWilliam J. McKenna
William J. McKenna
MGMihai Gheorghiade
Mihai Gheorghiade
BUBarry F. Uretsky
Barry F. Uretsky
KSKarl Swedberg
Karl Swedberg

11 May 2009 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
MGMartha Gulati
Martha Gulati
RCRhonda M. Cooper-DeHoff
Rhonda M. Cooper-DeHoff
CMCandace McClure
Candace McClure
BJB. Delia Johnson
B. Delia Johnson
LSLeslee J. Shaw
Leslee J. Shaw
CMC. Noel Bairey Merz
C. Noel Bairey Merz
Women with clinical findings suggestive of ischemia but without findings of obstructive coronary artery disease (CAD) on angiography represent a frequent clinical problem; predicting prognosis is challenging. The Women's Ischemia Syndrome Evaluation (WISE) study examined symptomatic women referred for clinically indicated coronary angiography and followed up for a mean 5.2 years. The St James Women Take Heart (WTH) Project enrolled asymptomatic, community-based women with no history of heart disease who were followed up for 10 years. We compared cardiovascular events (ie, myocardial infarction, stroke, and hospitalization for heart failure) and death in 540 WISE women with suspected ischemia but no angiographic evidence of obstructive CAD with those from a cohort of 1000 age- and race-matched WTH women. Compared with the WISE women, asymptomatic WTH women had a lower prevalence of obesity, family history of CAD, hypertension, and diabetes mellitus (P < .001). Five-year annualized event rates for cardiovascular events were 16.0% in WISE women with nonobstructive CAD (stenosis in any coronary artery of 1%-49%), 7.9% in WISE women with normal coronary arteries (stenosis of 0% in all coronary arteries), and 2.4% in asymptomatic WTH women (P < or = .002), after adjusting for baseline CAD risk factors. The cardiovascular events were most frequent in women with 4 or more cardiac risk factors, with the 5-year annualized cardiovascular event rate being 25.3% in women with nonobstructive CAD, 13.9% in WISE women with normal coronary arteries, and 6.5% in asymptomatic women (P = .003). Women with symptoms and signs suggestive of ischemia but without obstructive CAD are at elevated risk for cardiovascular events compared with asymptomatic community-based women.

7 July 2010 in JAMA
Verified
Journal Article
Open access
PDF file
RCRhonda M Cooper-Dehoff
Rhonda M Cooper-Dehoff
YGYan Gong
Yan Gong
EHEileen M. Handberg
Eileen M. Handberg
ABAnthony A. Bavry
Anthony A. Bavry
SDScott J. Denardo
Scott J. Denardo
CPCarl J. Pepine
Carl J. Pepine
The 1984 report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recognized that patients with diabetes mellitus represented a special population.1 In 1993, the fifth report of the Joint National Committee recommended that the treatment goal for patients with diabetes should reduce blood pressure (BP) to less than 130/85 mm Hg.2 This lower goal was based primarily on data from the 1501-patient cohort with diabetes enrolled in the Hypertension Optimal Treatment (HOT) trial,3 which suggested reduced cardiovascular outcomes for 501 patients assigned to a diastolic treatment goal of less than 80 mm Hg compared with those assigned to treatment goals that allowed for higher BP. Data from the United Kingdom Prospective Diabetes Study (UKPDS) group4,5 showed that patients with diabetes and hypertension assigned to a tight BP goal group had reduced macrovascular and microvascular outcomes. In 2002, the American Diabetes Association recommended that the BP treatment goal for patients with diabetes should be less than 130/80 mm Hg, which it reaffirmed in 2010.6-8

30 March 2018 in Clinical Science
Verified
Journal Article
Closed access
PDF file
SKSeungbum Kim
Seungbum Kim
RGRuby Goel
Ruby Goel
AKAshok Kumar
Ashok Kumar
YQYanfei Qi
Yanfei Qi
GLGil Lobaton
Gil Lobaton
MRMohan K. Raizada
Mohan K. Raizada
Recent evidence indicates a link between gut pathology and microbiome with hypertension (HTN) in animal models. However, whether this association exists in humans is unknown. Thus, our objectives in the present study were to test the hypotheses that high blood pressure (BP) patients have distinct gut microbiomes and that gut–epithelial barrier function markers and microbiome composition could predict systolic BP (SBP). Fecal samples, analyzed by shotgun metagenomics, displayed taxonomic and functional changes, including altered butyrate production between patients with high BP and reference subjects. Significant increases in plasma of intestinal fatty acid binding protein (I-FABP), lipopolysaccharide (LPS), and augmented gut-targetting proinflammatory T helper 17 (Th17) cells in high BP patients demonstrated increased intestinal inflammation and permeability. Zonulin, a gut epithelial tight junction protein regulator, was markedly elevated, further supporting gut barrier dysfunction in high BP. Zonulin strongly correlated with SBP (R2 = 0.5301, P<0.0001). Two models predicting SBP were built using stepwise linear regression analysis of microbiome data and circulating markers of gut health, and validated in a separate cohort by prediction of SBP from zonulin in plasma (R2 = 0.4608, P<0.0001). The mouse model of HTN, chronic angiotensin II (Ang II) infusion, was used to confirm the effects of butyrate and gut barrier function on the cardiovascular system and BP. These results support our conclusion that intestinal barrier dysfunction and microbiome function are linked to HTN in humans. They suggest that manipulation of gut microbiome and its barrier functions could be the new therapeutic and diagnostic avenues for HTN.